1. Home
  2. ANIX vs ATRA Comparison

ANIX vs ATRA Comparison

Compare ANIX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

SELL

Current Price

$2.68

Market Cap

114.0M

Sector

Health Care

ML Signal

SELL

Logo Atara Biotherapeutics Inc.

ATRA

Atara Biotherapeutics Inc.

SELL

Current Price

$8.84

Market Cap

94.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ANIX
ATRA
Founded
1982
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
94.2M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ANIX
ATRA
Price
$2.68
$8.84
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$9.75
★ $13.67
AVG Volume (30 Days)
★ 306.6K
36.6K
Earning Date
09-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
★ 122.52
EPS
★ N/A
N/A
Revenue
$210,000.00
★ $120,772,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,334.59
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.32
$3.92
52 Week High
$5.46
$19.15

Technical Indicators

Market Signals
Indicator
ANIX
ATRA
Relative Strength Index (RSI) 39.55 49.17
Support Level $2.62 $8.96
Resistance Level $3.09 $9.64
Average True Range (ATR) 0.14 0.67
MACD 0.01 0.04
Stochastic Oscillator 7.17 65.31

Price Performance

Historical Comparison
ANIX
ATRA

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Share on Social Networks: